As of 2025-09-18, the Relative Valuation of BioCryst Pharmaceuticals Inc (BCRX) is (3.55) USD. This relative valuation is based on P/E multiples. With the latest stock price at 7.70 USD, the upside of BioCryst Pharmaceuticals Inc based on Relative Valuation is -146.1%.
The range of the Relative Valuation is (3.22) - (4.01) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 18.9x - 26.1x | 22.3x |
| Forward P/E multiples | 17.2x - 23.6x | 19.4x |
| Fair Price | (3.22) - (4.01) | (3.55) |
| Upside | -141.8% - -152.1% | -146.1% |
| Date | P/E |
| 2025-09-17 | -45.26 |
| 2025-09-16 | -45.56 |
| 2025-09-15 | -45.26 |
| 2025-09-12 | -46.50 |
| 2025-09-11 | -47.44 |
| 2025-09-10 | -47.09 |
| 2025-09-09 | -47.50 |
| 2025-09-08 | -48.14 |
| 2025-09-05 | -48.61 |
| 2025-09-04 | -48.61 |
| 2025-09-03 | -48.73 |
| 2025-09-02 | -48.73 |
| 2025-08-29 | -48.85 |
| 2025-08-28 | -49.79 |
| 2025-08-27 | -50.08 |
| 2025-08-26 | -50.44 |
| 2025-08-25 | -49.32 |
| 2025-08-22 | -50.32 |
| 2025-08-21 | -49.26 |
| 2025-08-20 | -49.26 |
| 2025-08-19 | -48.67 |
| 2025-08-18 | -49.26 |
| 2025-08-15 | -49.20 |
| 2025-08-14 | -49.67 |
| 2025-08-13 | -50.14 |
| 2025-08-12 | -49.08 |
| 2025-08-11 | -48.20 |
| 2025-08-08 | -48.79 |
| 2025-08-07 | -49.08 |
| 2025-08-06 | -50.55 |
| 2025-08-05 | -49.14 |
| 2025-08-04 | -51.32 |
| 2025-08-01 | -46.73 |
| 2025-07-31 | -47.85 |
| 2025-07-30 | -48.32 |
| 2025-07-29 | -47.56 |
| 2025-07-28 | -48.55 |
| 2025-07-25 | -50.26 |
| 2025-07-24 | -50.26 |
| 2025-07-23 | -50.61 |
| 2025-07-22 | -50.85 |
| 2025-07-21 | -50.08 |
| 2025-07-18 | -50.61 |
| 2025-07-17 | -51.14 |
| 2025-07-16 | -50.49 |
| 2025-07-15 | -51.26 |
| 2025-07-14 | -52.67 |
| 2025-07-11 | -51.49 |
| 2025-07-10 | -52.20 |
| 2025-07-09 | -53.26 |